Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05061654
Other study ID # MRC-02-21-015
Secondary ID
Status Withdrawn
Phase Phase 4
First received
Last updated
Start date August 2022
Est. completion date June 2024

Study information

Verified date September 2021
Source Hamad Medical Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with blood cancers and those who received a bone marrow transplant frequently have low circulating white blood cell countS. Fever in patients with low white blood cell count requires early appropriate antibiotic treatment to prevent complications including death. Bacteria have increasingly become more resistant to existing antibiotic options. Ceftolozane-tazobactam is a newer type of antibiotic that has been shown to be safe and effective in infections caused by several types of resistant bacteria that can cause serious infections in individuals with low blood count. This study aims to examine the effectiveness of this antibiotic in these types of patients. Patients with blood cancer and those who have received a bone transplant will be offered the option to join this study if they develop unexplained fever. If informed consent is granted, they will receive ceftolozane-tazobactam on top of the usual care that such patients receive. The patients will then be followed very closely to check their response to the treatment and if they develop any untoward events. The study will include 164 patients over an estimated 2 year period. The study is funded by Merck & Co, the company that manufactures the study antibiotic. However, Merck & Co. will not be involved in the actual running of the study, the collection of the study results or their analysis and interpretation. The study protocol has been reviewed and approved by an independent research oversight committee.


Description:

The role of early appropriate empiric anti-bacterial therapy in reducing morbidity and mortality in patients with prolonged neutropenia has long being documented. The National Center for Cancer Care and Research (NCCCR) antibiograms for recent years showed increasing rates of ESBL-producing E. coli and K. pneumoniae, as well as reduced susceptibility of P. aeruginosa isolates to piperacillin-tazobactam. Ceftolozane-tazobactam is a newer β-lactam-β-lactamase inhibitor combination with a broad in-vitro spectrum that includes ESBL and AmpC-producing Enterobacterales, as well as multidrug resistant P. aeruginosa. The clinical efficacy and safety of ceftolozane-tazobactam was demonstrated in registrational randomized clinical trials in multiple settings. However, clinical experience with ceftolozane-tazobactam in patients with hematological malignancy or HSCT is very limited. The aim of this study is to explore the potential role of ceftolozane-tazobactam as empiric treatment for hematology patients with neutropenic fever of unknown origin. The primary objective is to assess the efficacy of ceftolozane-tazobactam as empiric anti-bacterial therapy for neutropenic fever in patients with hematological malignancy or HSCT. The study will be a prospective, non-comparative, single-arm, single center, open-label interventional study. Patients admitted to NCCCR with a malignant hematological diagnosis and/or HSCT will be screened daily for possible inclusion in the study. Participants will receive empiric therapy with ceftolozane-tazobactam intravenously. All remaining care will be consistent with standard clinical care for patients with neutropenic fever. The Primary endpoint will be treatment success at 72 hours of ceftolozane-tazobactam therapy without modification of anti-bacterial therapy. Treatment success is defined as a composite of defervescence, resolution of any baseline clinical signs of infection, microbiological eradication of any baseline bacterial pathogen, and no modification of anti-bacterial therapy by addition of or switch to an agent with microbiological activity against Enterobacterales or P. aeruginosa (except the addition of sulfamethoxazole-trimethoprim for P. jiroveci prophylaxis). The study will be conducted in full conformance with principles of the "Declaration of Helsinki", Good Clinical Practice (GCP), and within the laws and regulations of Ministry of Public Health in Qatar. Participation will be subject to written informed consent. The study is sponsored by Hamad Medical Corporation. Funding and medication supply is provided by Merck & Co (MSD) through its Investigator Initiated Studies Program. MSD will not have any role in data collection, data analysis or driving study conclusions.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 2024
Est. primary completion date January 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Hospitalized with an underlying diagnosis of hematological cancer or receipt of hematopoietic stem cell transplantation. - Age =18 years. - Absolute neutrophil count (ANC) of <0.5x10^9/L or <1.0x10^9/L with a predicted decline to <0.5x10^9/L within the next 2 days. - Oral temperature of = 38.3 °C once, = 38.0 °C lasting for at least 1 hour, or = 38.0 °C twice within 12 hours. Exclusion Criteria: - Allergy to cephalosporins. - Expected survival of =72 hours. - Expected ANC recovery within =72 hours. - Receipt of any antipseudomonal carbapenem therapy within the preceding 14 days. - Documented current or past infection or colonization with ceftolozane-tazobactam- resistant Enterobacterales or P. aeruginosa. - Pregnancy. - Previous enrollment in CEF-10 Study (subjects previously enrolled in this study cannot be enrolled again during subsequent episodes of neutropenic fever). - Ongoing therapy or planned continuation of therapy outside the National Center for Cancer Care and Research.

Study Design


Intervention

Drug:
Ceftolozane-tazobactam IV
Empiric Ceftolozane-tazobactam IV 3g over 1 hour every 8 hours. The dose will be reduced to 1.5g 8 hourly in patients with CrCl of 30-50 ml/min, and to 750mg every 8 hours in those with CrCl of 15-29 ml/min. Patients on hemodialysis will receive 2.25g loading dose followed by 450mg every 8 hours.

Locations

Country Name City State
Qatar Hamad Medical Corporation, National Center for Cancer Care and Research Doha

Sponsors (2)

Lead Sponsor Collaborator
Hamad Medical Corporation Merck Sharp & Dohme LLC

Country where clinical trial is conducted

Qatar, 

Outcome

Type Measure Description Time frame Safety issue
Other In-vitro susceptibility to ceftolozane-tazobactam of any Enterobacterales or P. aeruginosa isolated from the study subjects CLSI breakpoints 30 days
Primary Treatment success without modification of anti-bacterial therapy Treatment success is defined as a composite of defervescence, resolution of any baseline clinical signs of infection, microbiological eradication of any baseline bacterial pathogen, and no modification of anti-bacterial therapy by addition of or switch to an agent with microbiological activity against Enterobacterales or P. aeruginosa (except the addition of sulfamethoxazole-trimethoprim for P. jiroveci prophylaxis). 72 hours
Secondary Treatment success without modification of anti-bacterial therapy Treatment success is defined as a composite of defervescence, resolution of any baseline clinical signs of infection, microbiological eradication of any baseline bacterial pathogen, and no modification of anti-bacterial therapy by addition of or switch to an agent with microbiological activity against Enterobacterales or P. aeruginosa (except the addition of sulfamethoxazole-trimethoprim for P. jiroveci prophylaxis) 7 days
Secondary Days to defervescence Counted from the first oral temperature of <38oC which is sustained for =48 hours 30 days
Secondary 30-day survival Survival for 30 days from initiation of therapy 30 days
See also
  Status Clinical Trial Phase
Completed NCT04966156 - Cancer Rehab Program for Allogenic Bone and Marrow Transplant Patients - CaRE-4-alloBMT N/A
Recruiting NCT05942885 - Hypnosis: a Path to Appeasement N/A
Recruiting NCT05715047 - Intervention for Fatigue in HCT Recipients N/A
Recruiting NCT05142033 - Avera Cancer Sequencing and Analytics Protocol (ASAP)
Completed NCT06053918 - Research-Action in Hematology From Hospitalization to Home
Recruiting NCT05175508 - Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS Phase 2/Phase 3
Not yet recruiting NCT04822974 - TORQUETENOVIRUS IN CAR-T THERAPY: PREDICTION OF THE CRS N/A
Not yet recruiting NCT06279585 - Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD N/A
Recruiting NCT05753501 - Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies Phase 1
Recruiting NCT05481502 - An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors N/A
Not yet recruiting NCT04412135 - The Point of View of Hematological Cancer Patients and Their Loved Ones Regarding Spirituality
Completed NCT04235153 - CAncer, NUtrition and Taste - Validation of the CANUT-QVA Questionnaire on Eating Habits in Cancer Patients
Recruiting NCT05626764 - QUALITOP - Monitoring Multidimensional Aspects of QUAlity of Life After Cancer ImmunoTherapy, an Open Smart Digital Platform for Personalized Prevention and Patient Management
Active, not recruiting NCT04035447 - Symptom Management for YA Cancer Survivors N/A
Not yet recruiting NCT05602168 - Collection of Sequential Samples From Patients With Malignant Myeloid Hemopathy for the Study of Treatment Resistance N/A
Terminated NCT03955276 - An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme)
Recruiting NCT03091933 - Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) Phase 1/Phase 2
Withdrawn NCT01792882 - Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples
Recruiting NCT05493800 - Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT Phase 2
Active, not recruiting NCT05690230 - Improving Patient Experience: BMBA N/A